|
Partnership |
Project |
| Forest Laboratories |
Development, commercialisation and manufacturing agreement for roflumilast (Daxas®) in the United States.
See also press release |
Roflumilast is a once-daily oral treatment for patients suffering from symptomatic Chronic Obstructive Pulmonary Disease (COPD), currently in registration.
See also registration |
| Merck & Co. |
Commercialisation agreement for roflumilast (Daxas®) in major European markets and Canada.
See also press release |
Co-promotion of Daxas® in Germany, France, Spain, Italy, Portugal and Canada. Merck & Co. will exclusively commercialise Daxas® in the UK.
See also clinical trial project |
| Sepracor |
Exclusive development, marketing and commercialisation rights for Ciclesonide in the United States.
See also press release |
Ciclesonide is Nycomed’s patented corticosteroid with a novel principle of action. It is the active ingredient in the Alvesco® inhalation Aerosol for the treatment of asthma and in the Omnaris® Nasal Spray for the treatment of allergic rhinitis.
See also clinical trial project |
| NPS Pharmaceuticals |
Licensing of rights to develop and commercialise teduglutide outside the United States, Canada and Mexico.
See also press release |
A potential first-in-class drug, teduglutide is developed for the treatment of gastrointestinal disorders and matches Nycomed’s capabilities in development and marketing in the gastroenterology field.
See also clinical trial project |
| Immunomedics |
Exclusive worldwide rights to develop, manufacture and commercialise the sub-cutaneous formulation of veltuzumab for all non-cancer indications.
See also press release |
Nycomed is developing veltuzumab in rheumatoid arthritis as the primary indication. Veltuzumab presents a significant enhancement to Nycomed’s autoimmune and inflammation pipeline.
See also clinical trial project |
| Micromet |
Collaboration on the development of anti-GM-CSF antibodies.
See also press release |
Anti-GM-CSF antibodies may be useful in the treatment of inflammatory and autommune diseases. The lead product candidate is MT203, a human antibody.
See also clinical trial project |
| Durect |
Licence agreement and joint development program for SABER™-bupivacaine (Optesia®).
See also press release |
Optesia® is a long-acting and local pain relief depot for the treatment of post-surgical pain currently in phase II trials.
See also clinical trial project |
| EffRx |
Licensing agreement for EX101 (effervescent alendronate)
See also press relase |
EX101 is a once weekly administration of an effervescent formulation of alendronate (bisphosphonate) for treatment of post-menopausal osteoporosis.
See also clinical trial project |